Insilico Medicine Featured in Harvard Business School Case Study on Rentosertib

The page describes an Eli Lilly partnership with Insilico Medicine, expanded in late 2025 from an earlier 2023 software licensing agreement, for compound generation and optimization against Lilly-defined targets. Total potential deal value is stated as $100+ million. The page separately notes Eli Lilly was a cornerstone investor in Insilico's 2025 Hong Kong IPO.

Insilico Medicine is an AI-native biotech running its own generative-chemistry drug-discovery platform (Pharma.AI), and licensing it through partnerships with major pharma companies.

This sits in the Build stage of the AI use-case lifecycle: Named examples from the foundation-model labs and platforms pharma teams use to actually construct, train and generate the model or application.